Dihexa is studied for its proposed capacity to function as a potentiator of hepatocyte growth factor (HGF) at the MET receptor tyrosine kinase, rather than acting as a direct receptor agonist
Studies confirm 50% drops by midlife, linking to aging symptoms.[1][9] Restoring NAD+ has been shown in animal studies to improve lifespan and healthspan, with human trials indicating benefits in muscle function and cognitive performance
Regulatory Timeline and Expectations CagriSema (Cagrilintide + Semaglutide): FDA review ongoing for obesity indication European Medicines Agency (EMA) submission completed Potential approval expected in late 2026 or early 2027 Would represent first approved amylin analogue combination therapy Cagrilintide Monotherapy: Less likely to be pursued as standalone therapy Combination approaches show superior efficacy May remain primarily a research tool Emerging Research Questions Key questions driving current research include: Optimal combination partners Beyond semaglutide, which peptides pair best with cagrilintide
While regenerative medicine falls under the Formation umbrella, it operates as its own clinical focus, separate from the minimally invasive procedures and minimally invasive treatments offered on the aesthetic side of the practice
Additionally, those with a history of allergic reactions to vitamin B12 or other medications should avoid these injections